| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.4 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.4 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.051 | 0.4 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.031 | 0.4 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.06 | 0.4 |